Fujian Haixi Pharmaceuticals Co., Ltd.
Research Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) on Bullrun: market cap HKD 12.73B, P/E 65.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2637.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 12.73B
- P/E65.5
- Financial periodFY2025
- RevenueCNY 582.36M
- Net incomeCNY 177.03M
- Free cash flowCNY 114.96M
- Gross margin83.4%
Valuation Snapshot
latest market cap is HKD 12.73B; P/E is 65.5.
Peer valuation comparison
Latest P/E is 65.51x versus a Healthcare sector median of 21.69x (202.0% above).
Latest P/E is 65.51x versus a China median of 16.26x (302.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 582.36M | CNY 177.03M | CNY 114.96M | 83.4% | n/a | CNY 645.05M | CNY 110.15M | CNY 1.59B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 12.73B | 65.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Fujian Haixi Pharmaceuticals Co., Ltd.
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fujian Haixi Pharmaceuticals Co., Ltd.'s market cap?
Fujian Haixi Pharmaceuticals Co., Ltd.'s market capitalization is HKD 12.73B.
What is Fujian Haixi Pharmaceuticals Co., Ltd.'s P/E ratio?
Fujian Haixi Pharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 65.5.
What does Fujian Haixi Pharmaceuticals Co., Ltd. do?
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services.